World's Best Scientists 2026 revealed!
Marc Bourlière

Marc Bourlière

D-Index & Metrics

Medicine

D-Index
84
Citations
29333
World Ranking
14985
National Ranking
482

Overview

Marc Bourlière is affiliated with Hôpital Saint Joseph in France. Their research primarily focuses on medicine, with a concentration in hepatology and epidemiology. Their work also extends into surgery, infectious diseases, and oncology.

The scientist's research covers key topics such as liver disease diagnosis and treatment, hepatitis C virus research, hepatitis B virus studies, liver disease and transplantation, hepatocellular carcinoma treatment and prognosis, cholangiocarcinoma and gallbladder cancer studies, and liver diseases and immunity.

Marc Bourlière's frequent coauthors include Nathalie Ganne-Carrié, Victor de Lédinghen, Fabrice Carrat, Stanislas Pol, and Fabien Zoulim.

Their publications have appeared regularly in several prominent venues, including:

  • Journal of Hepatology
  • Clinics and Research in Hepatology and Gastroenterology
  • Liver International
  • Journal of Viral Hepatitis
  • JHEP Reports

Representative recent papers authored by or involving Marc Bourlière include:

  • "Advancing the global public health agenda for NAFLD: a consensus statement," 2021, Nature Reviews Gastroenterology & Hepatology
  • "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials," 2020, Journal of Hepatology
  • "Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial," 2023, The Lancet
  • "Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial," 2023, The Lancet Oncology
  • "Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial," 2021, Nature Medicine

Best Publications

  • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

    Christophe Hézode;Nicole Forestier;Geoffrey Dusheiko;Peter Ferenci

  • Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

    Vlad Ratziu;Vlad Ratziu;Stephen A. Harrison;Sven Francque;Pierre Bedossa

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

    Marion G. Peters;H. W. Hann;Paul Martin;E. Jenny Heathcote

  • Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection

    Marc Bourlière;Stuart C. Gordon;Steven L. Flamm;Curtis L. Cooper

  • Advancing the global public health agenda for NAFLD: a consensus statement.

    Jeffrey V Lazarus;Henry E Mark;Quentin M Anstee;Juan Pablo Arab

  • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3

    Stefan Zeuzem;Rolf Hultcrantz;Marc Bourliere;Tobias Goeser

  • Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

    Fabrice Carrat;Hélène Fontaine;Céline Dorival;Mélanie Simony

  • Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.

    Caroline Charlier;Élodie Perrodeau;Alexandre Leclercq;Alexandre Leclercq;Benoît Cazenave

  • Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

    Pierre Nahon;Pierre Nahon;Valérie Bourcier;Richard Layese;Etienne Audureau

  • Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

    John G. McHutchison;Geoffrey Dusheiko;Mitchell L. Shiffman;Maribel Rodriguez-Torres

  • Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890

    Christophe Hézode;Hélène Fontaine;Céline Dorival;Dominique Larrey

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • Meta-analyses of FibroTest diagnostic value in chronic liver disease

    Thierry Poynard;Rachel Morra;Philippe Halfon;Laurent Castera

  • All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

    Michael Peter Manns;Stanislas B Pol;Ira M Jacobson;Patrick M Marcellin

  • Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

    Mark Sulkowski;Christophe Hezode;Jan Gerstoft;John M Vierling

  • Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

    Stephen A Harrison;Vincent Wai-Sun Wong;Takeshi Okanoue;Natalie Bzowej

  • Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

    Marc Bourlière;Jean Pierre Bronowicki;Victor de Ledinghen;Christophe Hézode

  • Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study

    Jean-Pierre Zarski;Nathalie Sturm;Jérôme Guechot;Adeline Paris

  • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients

    Stefan Zeuzem;Rolf Hultcrantz;Marc Bourliere;Tobias Goeser

Frequent Co-Authors

Jean-Pierre Bronowicki
Jean-Pierre Bronowicki University Hospital of Nancy
Philippe Halfon
Philippe Halfon Université Paris Cité
Stanislas Pol
Stanislas Pol Université Paris Cité
Dominique Larrey
Dominique Larrey University of Montpellier
Victor de Ledinghen
Victor de Ledinghen Grenoble Alpes University
Albert Tran
Albert Tran Inserm : Institut national de la santé et de la recherche médicale
Christophe Hézode
Christophe Hézode Université Paris Cité
Laurent Alric
Laurent Alric Federal University of Toulouse Midi-Pyrénées
Patrick Marcellin
Patrick Marcellin Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare career paths or online study options can offer flexibility and unique opportunities, especially for those interested in the medical field in the USA. For students who hold a non-nursing bachelor’s degree but wish to leverage their skills in the healthcare sector, direct entry msn programs for non-nursing majors online provide a streamlined transition into advanced nursing roles.

If you’re looking for accessible nursing pathways, direct entry nursing programs offer a chance to begin your nursing career even if your prior studies were in a different field. These programs are typically designed to fast-track your entry into the profession.

For those interested in administrative or support careers in healthcare, the best medical billing and coding schools online offer flexible study options, often with financial aid. These are suited for individuals who want a vital role in healthcare systems without direct patient care.

Finally, some accelerated nursing degrees, like absn programs that don't require teas, provide an alternative path for those who do not want to take standardized entrance exams, further expanding access to nursing careers.

Best Scientists Citing Marc Bourlière

Trending Scientists

Recently Published Articles